Healthequity Inc’s recent filing unveils that its EVP, General Counsel Ladd Delano unloaded Company’s shares for reported $0.14 million on Oct 20 ’25. In the deal valued at $92.07 per share,1,500 shares were sold. As a result of this transaction, Ladd Delano now holds 76,979 shares worth roughly $7.68 million.
Then, Delano Ladd bought 977 shares, generating $86,530 in total proceeds.
Before that, James M. Lucania bought 2,393 shares. Healthequity Inc shares valued at $211,942 were divested by the Officer at a price of $88.57 per share.
A number of analysts have revised their coverage, including Raymond James’s analysts, who increased its forecast for the stock in late March from “an Outperform” to “a Strong buy”. Mizuho began covering HQY with “an Outperform” recommendation on December 04, 2024. Goldman started covering the stock on November 15, 2024. It rated HQY as “a Neutral”.
Price Performance Review of HQY
On Monday, Healthequity Inc [NASDAQ:HQY] saw its stock jump 6.53% to $99.83. Over the last five days, the stock has gained 5.29%. Healthequity Inc shares have risen nearly 1.92% since the year began. Nevertheless, the stocks have risen 4.04% over the past one year. While a 52-week high of $116.65 was reached on 06/05/25, a 52-week low of $74.07 was recorded on 04/07/25.
Levels Of Support And Resistance For HQY Stock
The 24-hour chart illustrates a support level at 96.27, which if violated will result in even more drops to 92.72. On the upside, there is a resistance level at 102.11. A further resistance level may holdings at 104.40.
How much short interest is there in Healthequity Inc?
A steep rise in short interest was recorded in Healthequity Inc stocks on 2025-10-15, dropping by -0.17 million shares to a total of 4.24 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 4.41 million shares. There was a decline of -4.06%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 04, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $101 price target.
